We report a case of combined squamomelanocytic tumor of the skin. Clinically, the lesion was felt to be a squamous cell carcinoma. Histologically, it was characterized by large epithelioid cells admixed with basaloid cells with central squamous differentiation. Immunohistochemical staining showed both cell populations to be reactive with Melan A, BEREP4, and Pan Keratins. Ultrastructural studies revealed simultaneous features of squamous differentiation (dense cytoplasmic tonofilaments with well-developed desmosomes) and melanocytic differentiation (mature/pigmented melanosomes) in the same cell population. This is the second reported case in the English literature with documented biphenotypic or divergent differentiation at the ultrastructural level. The behavior of squamomelanocytic tumor is uncertain given the rarity of reported cases.
INTRODUCTION
Squamomelanocytic tumor (SMT) is an uncommon cutaneous neoplasm composed of an admixture of melanocytic and squamous cellular phenotypes. In the large literature review on cutaneous collision tumors, Boyd and Rapini 1 found 0 SMTs of 69 collisions. In a series of 78,000 primary cutaneous cancers, Pierard et al 2 identified 106 basosquamous carcinomas and 0 SMTs. In fact, Novick et al 3 reported the first case of squamous cell carcinoma (SCC) admixed with malignant melanoma (MM). Ever since, numerous terms have been used to describe SMT, such as combined, colliding, biphasic, contiguous, or colonizing. Furthermore, some authors reported tumors that arose adjacent to one another as combined tumors, whereas other tumors that were intimately intermixed were called collision tumors, and in a few cases, both terms were used. 4 In a case series from 1999, Pool et al 5 described 4 cutaneous neoplasms composed of an admixture of 2 cell populations including both melanocytic and squamous phenotypes which they referred to as "squamomelanocytic tumor." The authors were the first to introduce SMT as a unique clinicopathological entity. To date, a total of 11 similar cases of SMT were reported in the English literature. True biphenotypia as defined by Braun-Falco 4 includes coexpression of different immunohistochemical markers and/or ultrastructural evidence of differentiation in 2 different cell lines within the same cell. Herein, we report a rare case of true biphenotypic SMT exhibiting squamous and melanocytic phenotypes. Additional immunohistochemical and ultrastructural studies are presented to provide further insights into the proposed histopathogenic pathway underlying the development of this tumor.
CLINICAL CASE
A 78-year-old man presented to the Dermatology clinic for a left retroauricular "mass". A shave biopsy was performed. Gross examination showed a flat piece of skin measuring 0.6 · 0.4 · 0.1 cm with a centrally located crusted pink papule measuring 0.5 · 0.4 cm. Low-power magnification showed a nodular proliferation with bulbous edges centered in the superficial dermis. The mass was focally connected to the overlying epidermis without evidence of ulceration. The neoplasm infiltrated the dermis as irregular bulbous projections ( Fig. 1 ). On high-power examination, the tumor consisted of sheets and irregular nests of large atypical heavily pigmented epithelioid and/or dendritic cells with scant cytoplasm intermingled with basaloid cells and atypical squamoid cells with dark nuclei and abundant eosinophilic cytoplasm. Some of these cells showed intercellular desmosomal bridges. Squamous differentiation (Keratin pearls with heavy pigmentation) was present centrally. The actual depth of the tumor was difficult to ascertain because it was centered in the dermis with only focal connection to the epidermis. Atypical mitotic figures were identified without evidence of necrosis ( Fig. 1 ). No evidence of atypical melanocytic proliferation was present in the overlying epidermis. Adjacent skin showed moderate solar elastosis. Both types of lesional cells (basaloid and epithelioid/dendritic) showed positive immunoreactivity with melanocytic marker, MART-1, and epithelial markers, Keratin AE1/AE3 and Ber-EP4, simultaneously ( Fig. 2) . Ultrastructural studies by transmission electron microscopy revealed dense cytoplasmic tonofilaments with well-developed desmosomes features of squamous differentiation. Mature/pigmented melanosomes were identified in the same cell population. Also, many melanosomes in variable states of pigmentation or unpigmented premelanosomes were identified, highly suggesting that their genesis occurred within the same tumor cells ( Fig. 3 ). These findings are consistent with simultaneous dual melanocytic and squamous differentiation. Thus, we believe that this neoplasm represents a rare example of biphenotypic SMT.
DISCUSSION
SMT is an uncommon yet well-defined clinicopathological entity. To date, only 11 cases have been reported. Our review of the literature shows that the face is the most common site of predilection for this tumor. Other sites include upper extremities, the back, and the legs ( Table 1) . SMT tends to occur in elderly population with mean age of 67 years at diagnosis. It presents as nodular expansile mass with bulbous infiltration within the dermis. Connection with the epidermis is present in the majority of the reported cases except when the tumor presents as an isolated dermal nodule ( Table 2 ). In all of the previously reported cases including our case, atypical epithelial cells exhibiting squamous differentiation with occasional basaloid cells and large atypical pigmented epithelioid cells were present on histological sections. Solar elastosis is not consistently present and has been identified in 4 of the 11 reported cases ( Table 2) . Intraepidermal proliferation of atypical single unit melanocytes (Lentigo Maligna) can be present in the overlying and/or adjacent epidermis in association with solar damage or independently ( Table 2 ). The origin of SMT is still disputed. The exact etiology of bidirectional/dual differentiation is unclear although several hypotheses have been proposed. The 2 main proposed theories are the divergent (ie, the tumor exhibits neoplastic heterogeneity, containing 2 different clones of neoplastic cells) and the convergent (ie, formation of a hybrid/ chimeric neoplastic cell that has retained properties from both squamous and melanocytic cells). 10 Other proposed theories include aberrant expression of immunohistochemical markers by the neoplastic cells. 11 Although MMs may rarely express keratins, squamous differentiation with keratin pearl formation, as seen in our case, do not occur. 5 Thus, it is unlikely that our tumor represents a MM with aberrant cytokeratin expression. In 1984, Rosen et al 10 described a SMT that differed from all previous case reports in that it showed bidirectional differentiation with the same cells expressing both epithelial and melanocytic markers simultaneously. Our case shows a similar pattern of staining with a dual combined immunoreacticity with MART-1 and Pan Keratin in the "chimeric/stem" cells. This finding can be regarded as a sign of biphenotypia favoring the aforementioned convergent theory. This is further supported by the ultrastructural findings of premelanosomes and mature melanosomes in the same cells along with tonofilaments and hemidesmosomes, which is consistent with simultaneous melanocytic and squamous differentiation, respectively ( Fig. 3) . To the best of our knowledge, no ultrastructural studies are available for any of the previously reported cases. [5] [6] [7] [8] [9] [10] In 9 of the previously reported cases, immunohistochemical studies showed an admixed/intermingled pattern of immunostaining for both melanocytic and epithelial markers in the neoplastic, melanocytic, and epithelial (squamous) cells, respectively. Thus, the authors maintained a "collision tumor" or "divergent theory" in most of these cases based on these immunohistochemical findings. 7, 8 In fact, only 2 reported cases showed evidence of biphenotypia (combined S-100/keratin positivity in the same cells) by immunohistochemistry. Furthermore, ultrastructural studies were available in only 1 case to ascertain the true biphenotypic nature of the tumor. 10 Random genomic depression of the neoplastic cells or dedifferentiation of the neoplastic cells to a common stem cell precursor has also been proposed by some authors as a histogenic pathway for such tumors. 10, 12 This theory risks refuting the common belief that melanocytes are derived from the neural crest, instead suggesting an ectodermal origin. 12 Pseudocarcinomatous hyperplasia associated with a melanoma has been reported by Kamino et al 13 in a series of 4 melanomas. This finding leads to another theory as for the origin of SMT; the SCC component is believed to derive from an exuberant pseudoepitheliomatous hyperplasia near or within the MM tumor bed. 13 Our case showed no evidence of pseudoepitheliomatous hyperplasia. Furthermore, both large epithelioid and basaloid cells were atypical and showed increased mitotic activity with focal atypical mitotic figures. These findings suggest that these cells are neoplastic rather than hyperplastic per se. Thus, this theory cannot be maintained in our case. Melanocytic colonization theory has been postulated in an attempt to provide an explanation for the pathogenesis of SMTs. It is known that SCCs can be colonized by non-neoplastic dendritic melanocytic cells. 14, 15 In this instance, melanocytes lack cytologic atypia, irregular nesting, or adnexal involvement which suggests a true neoplastic process rather than a simple colonization. Our case showed sheets and irregular nests of large epithelioid cells with prominent cytologic atypia. The cells were labeled with both melanocytic (MART-1) and squamous markers (Keratin AE1/AE3, Ber-EP4). This constellation of findings along with the pigmentation and overall morphology are evidence of the neoplastic nature of these cells rather than a simple colonization process. The "collision" theory emerged as another means to explain histopathogenesis of peculiar SMTs. A collision tumor is an intimate admixture of 2 immunophenotypically distinct cell populations. That is, a melanoma cell population highlighted by melanocytic markers and a second SCC population highlighted by epithelial markers. These 2 populations can be adjacent or sometimes intermingled with each other. 7 The "collision" phenomenon has been suggested as a putative mechanism for tumor development in 9 of the 11 reported SMT cases. Our case does not represent a collision tumor given the simultaneous staining of the same cell population with melanocytic (MART-1) and epithelial (Keratin AE1/AE3) markers (Fig. 2) . Moreover, the shared immunoreactivity to Anti-EpCAM antibody (Ber-EP4) of both the melanocytic and squamous component strongly suggests the potential origin of this tumor from a distinctive subset of cells with autonomous differentiatiating potential. EpCAM is a morphoregulating molecule from the family of cell adhesion receptors whose role in the maintenance of pluripotent cell regulation and differentiation has been highlighted in numerous works. 16, 17 In addition, EpCAM constitutes a reliable marker for the identification of induced pluripotent stem cells and for tumor-initiating cells. 18, 19 Thus, by labeling with Anti-EpCAM antibody (Ber-EP4) antibody, †The IHC pattern refers to the pattern of staining with MART1/S100 or S100/HMB45 and Keratins. Intermingled is when melanocytes and squamous cells express specific markers separately while being admixed/intermixed morphologically.
‡Combined/biphenotypia is when both melanocytic and epithelial markers are expressed by the same cells. NA, not applicable; IHC, Immunohistochemistry.
these tumorigenic squamomelanocytic cells could be exhibiting stem cell properties of self-renewal and ability to produce a heterogeneous progeny from a single precursor. Heterologous differentiation (ie, rhabdoid melanomas) is described in melanomas. Few cases of rhabdoid melanoma have been reported, most of which were found in metastatic lesions. 20 Melanoma cells in these cases expressed S100 solely and lacked immunoreactivity with MART1, HMB45, microphthalmia transcription factor, smooth muscle actin and desmin. 20, 21 When available, ultrastructural studies showed lack of melanocytic differentiation in the tumor cells (ie, premelanosomes and mature pigmented melanosomes). 20 Based on these findings, authors considered these rhabdoid melanomas as "dedifferentiated" melanomas. One could hypothesize that the squamous component in our tumor is the result of a heterologous differentiation (ie, melanocytes undergoing a squamous metaplastic process with subsequent malignant transformation of these squamous cells). Yet, the ultrastructural findings (presence of premelanosomes and desmosomes in the same cells) and the dual expression of melanocytic (MART-1) and epithelial (Keratin AE1/AE3 and Ber-EP4) markers refute this hypothesis and favor that of a stem cell population that is evolving into a dual melanocytic and squamous differentiation. Melanocytic matricoma is a rare neoplasm that is important to consider in the differential diagnosis of our case, given overlapping morphological features. These tumors show a double positive nuclear and cytoplasmic immunoreactivity in the peripheral basaloid cells and tend to present as separate nodules without epidermal connection. 22 In a study by Yamashita et al, 23 the authors demonstrated a close functional link between EpCAM expression and the activation of Wnt-b-catenin signaling suggesting that EpCAM may serve as an excellent biomarker for the activation of the canonical b-catenin pathway. Indeed, aberrant signaling by the Wnt-b-catenin pathway is linked to a plethora of human neoplastic processes, and its expression is not restricted to melanocytic matricomas only. In our case, the presence of epidermal connection with the tumor nodule, the simultaneous staining of the same cells with melanocytic and epithelial markers, and the ultrastructural findings favored the diagnosis of SMT over that of a melanocytic matricoma. SMTs have an unknown biologic potential with unpredictable behavior. 24 The rarity of these cases and the lack of consensus concerning their classification impeded reaching clear information about their behavior. So far, no metastases have been reported with SMT. When follow-up was available, the overall disease-free survival ranged from 8 months to 9 years (average follow-up time of 20 months) in the reported cases (Table 1) . No clinical follow-up was available in our case. To date, the case reported by Rosen et al 10 in 1984 is the only true example of biphenotypia with dual differentiation proven by both immunohistochemical and ultrastructural studies. Similarly, ours is the second case providing ultrastructural and immunhistochemical findings supporting the "convergent" theory in SMT development. Additional studies are needed to validate our findings and to further elucidate the histogenic pathway for SMT. The rarity of these tumors renders this task difficult.
